Company intelligence / Profile preview
New-Bio
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
NewBio Therapeutics is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of next-generation antibody-drug conjugates (ADCs) and monoclonal antibodies for oncology. Founded in 2011, the company developed a proprietary ADC platform featuring novel linker and payload technologies, such as trimaleimide linkers, designed to improve the stability and therapeutic window of cancer treatments. Its lead candidates include NBT828 (also known as GB251), a HER2-targeting ADC in Phase 1 trials for breast cancer, and NBT508, a CD79b-targeting ADC for B-cell malignancies. In 2022, NewBio Therapeutics was acquired by Novocodex, a subsidiary of Zhejiang Medicine, to bolster Novocodex's ADC pipeline and technology capabilities.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Genor BiopharmaTot BiopharmNovocodex
Beyond the preview
Go deeper on New-Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on New-Bio.